Meyer J, Kelly S, Gidley J, Lansing J, Smith S, Churchill S
Trials. 2024; 25(1):663.
PMID: 39375728
PMC: 11460085.
DOI: 10.1186/s13063-024-08495-x.
Kawakami S, Okada N, Satomura Y, Shoji E, Mori S, Kiyota M
Cereb Cortex. 2024; 34(7.
PMID: 39049465
PMC: 11269430.
DOI: 10.1093/cercor/bhae284.
Hidese S, Matsuo J, Ishida I, Yokota Y, Ota M, Hattori K
PCN Rep. 2024; 1(2):e18.
PMID: 38868634
PMC: 11114436.
DOI: 10.1002/pcn5.18.
Takeshima M, Umakoshi A, Omori Y, Yoshizawa K, Ogasawara M, Kudo M
Psychopharmacology (Berl). 2024; 241(8):1555-1563.
PMID: 38538921
PMC: 11269321.
DOI: 10.1007/s00213-024-06581-1.
Shimamoto M, Ishizuka K, Ohtani K, Inada T, Yamamoto M, Tachibana M
Neuropsychopharmacol Rep. 2023; 44(1):115-120.
PMID: 38115795
PMC: 10932776.
DOI: 10.1002/npr2.12404.
A novel set of volatile urinary biomarkers for late-life major depressive and anxiety disorders upon the progression of frailty: a pilot study.
Fujita A, Ihara K, Kawai H, Obuchi S, Watanabe Y, Hirano H
Discov Ment Health. 2023; 2(1):20.
PMID: 37861875
PMC: 10501039.
DOI: 10.1007/s44192-022-00023-0.
Feasibility and Preliminary Effectiveness of Behavioral Activation for Patients with Cancer and Depression in Japan.
Hirayama T, Ogawa Y, Yanai Y, Shindo A, Tanaka M, Suzuki S
Palliat Med Rep. 2023; 4(1):150-160.
PMID: 37457329
PMC: 10345282.
DOI: 10.1089/pmr.2023.0020.
Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial.
Ito M, Horikoshi M, Kato N, Oe Y, Fujisato H, Yamaguchi K
Psychol Med. 2023; 53(7):3009-3020.
PMID: 37449485
PMC: 10235654.
DOI: 10.1017/S0033291721005067.
Effect of Personality Traits on Sustained Remission Among Patients with Major Depression: A 12-Month Prospective Study.
Nogami W, Nakagawa A, Katayama N, Kudo Y, Amano M, Ihara S
Neuropsychiatr Dis Treat. 2022; 18:2771-2781.
PMID: 36465145
PMC: 9717585.
DOI: 10.2147/NDT.S384705.
Obsessive-Compulsive Disorder with Psychotic Features: Is It a Clinical Entity?.
Okamura Y, Murahashi Y, Umeda Y, Misumi T, Asami T, Itokawa M
Healthcare (Basel). 2022; 10(10).
PMID: 36292356
PMC: 9601831.
DOI: 10.3390/healthcare10101910.
Benefits of group compassion-focused therapy for treatment-resistant depression: A pilot randomized controlled trial.
Asano K, Tsuchiya M, Okamoto Y, Ohtani T, Sensui T, Masuyama A
Front Psychol. 2022; 13:903842.
PMID: 36033032
PMC: 9415126.
DOI: 10.3389/fpsyg.2022.903842.
Relationship among psychotic features, benzodiazepine receptor agonists, and rehospitalization in patients with electroconvulsive therapy-responsive major depressive disorder: A retrospective 2-year observational study.
Umakoshi A, Takeshima M, Itoh Y, Yamamoto M, Shibata N, Ogasawara M
Neuropsychopharmacol Rep. 2022; 42(4):449-456.
PMID: 35866441
PMC: 9773724.
DOI: 10.1002/npr2.12282.
Application of the Unified Protocol for a Japanese Patient with Post-Traumatic Stress Disorder and Multiple Comorbidities: A Single-Case Study.
Kato N, Ito M, Matsuoka Y, Horikoshi M, Ono Y
Int J Environ Res Public Health. 2021; 18(21).
PMID: 34770156
PMC: 8582839.
DOI: 10.3390/ijerph182111644.
Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.
Sado M, Koreki A, Ninomiya A, Kurata C, Mitsuda D, Sato Y
Psychiatry Clin Neurosci. 2021; 75(11):341-350.
PMID: 34459077
PMC: 9293226.
DOI: 10.1111/pcn.13298.
Effectiveness of attachment-based family therapy compared to treatment as usual for depressed adolescents in community mental health clinics.
Waraan L, Rognli E, Czajkowski N, Aalberg M, Mehlum L
Child Adolesc Psychiatry Ment Health. 2021; 15(1):8.
PMID: 33579332
PMC: 7881666.
DOI: 10.1186/s13034-021-00361-x.
Moderation of treatment effects by parent-adolescent conflict in a randomised controlled trial of Attachment-Based Family Therapy for adolescent depression.
Rognli E, Waraan L, Czajkowski N, Aalberg M
Scand J Child Adolesc Psychiatr Psychol. 2021; 8:110-122.
PMID: 33564627
PMC: 7863725.
DOI: 10.21307/sjcapp-2020-011.
Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients.
Imai H, Noma H, Furukawa T
Eur Arch Psychiatry Clin Neurosci. 2020; 271(3):521-526.
PMID: 32715345
DOI: 10.1007/s00406-020-01173-4.
Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study.
Hidese S, Hattori K, Sasayama D, Tsumagari T, Miyakawa T, Matsumura R
Transl Psychiatry. 2020; 10(1):161.
PMID: 32439851
PMC: 7242469.
DOI: 10.1038/s41398-020-0843-5.
Neural and clinical changes of cognitive behavioural therapy versus talking control in patients with major depression: a study protocol for a randomised clinical trial.
Katayama N, Nakagawa A, Kurata C, Sasaki Y, Mitsuda D, Nakao S
BMJ Open. 2020; 10(2):e029735.
PMID: 32102803
PMC: 7045124.
DOI: 10.1136/bmjopen-2019-029735.
Augmentation of Positive Valence System-Focused Cognitive Behavioral Therapy by Inaudible High-Frequency Sounds for Anhedonia: A Trial Protocol for a Pilot Study.
Ito M, Miyamae M, Yokoyama C, Yamashita Y, Ueno O, Maruo K
JAMA Netw Open. 2019; 2(11):e1915819.
PMID: 31747035
PMC: 6902816.
DOI: 10.1001/jamanetworkopen.2019.15819.